Onychomycosis

TOPICA Elects G. Kirk Raab as Chairman of the Board

... The company is also developing luliconazole for onychomycosis (nail and nail bed fungal infections). onychomycosis affects approximately 35 million people in the ... treatment. The potential annual U.S. market for onychomycosis treatment is estimated at approximately $3 ...

TOPICA Begins Phase 2 Clinical Trial of Potent Antifungal, Luliconazole, in Athlete's Foot

... the company is developing luliconazole for onychomycosis (nail and nail bed fungal infections) and plans to move ahead with clinical development of onychomycosis shortly. The company's successful preclinical ... or "delivery enhancement" to cross the nail. onychomycosis affects approximately 35 million people in the ...

NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009

... its novel topical treatments for herpes labialis, onychomycosis and tinea capitis. The new data will be delivered ... Antifungal, Against the Major Pathogens of onychomycosis Poster # P2423, 12:20 p.m. -- Antifungal ... Nanoemulsion, Against Rare Fungal Pathogens of onychomycosis Poster # P2505, 2:00 p.m. -- Investigator ...

Bay Harbor Podiatry Group Launches New Revolutionary Laser Treatment for Nail Fungus

... Most Effective Safe, Quick & Painless Treatment to Eliminate Stubborn onychomycosis TORRANCE, Calif., June 10 /PRNewswire/ -- Bay Harbor Podiatry Group ... Patients can expect to see healthy nails within 8 - 10 months. onychomycosis affects approximately 35 million people in the U.S. and almost 50% of the ...

While Health Clubs Say No to 'Canckles,' Leading Podiatrists Say No to Toenail Fungus

... deformation and discoloration of the nails. While taking precautions, such as always wearing shoes in public places and keeping feet dry, onychomycosis is a very contagious infection and spreads easily with even the slightest contact. Bay Harbor Podiatry Group is one of the first medical ...

Bob Gold & Associates Steps Up as Marketing & PR Agency for Bay Harbor Podiatry Group

... and public relations efforts for the launch of the group's revolutionary new laser treatment that is 88% effective at eliminating toenail fungus ( onychomycosis ). "We finally have an unmatched effective treatment for nail fungus, and we're proud to be the first to offer this in the Los Angeles South ...

NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results

... announced a global agreement with Galderma, S.A. to develop and commercialize Aganocide compounds for all major dermatological conditions, excluding onychomycosis (nail fungus). Under the terms of the agreement, NovaBay expects to receive up to $50 million from Galderma upon achievement of certain development ...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

... for the treatment of diabetic foot infection that has already completed two Phase 3 clinical trials; EcoNail, a novel topical treatment for onychomycosis that completed a Phase 2 clinical trial; and two proprietary dermatology drug platforms, SEPA(R) and MacroDerm. "The acquisition of MacroChem ...

New topical approach to treating nail fungus circumvents problems with current therapy

... per gram of tissue are required for NB-002 to kill fungal infections. Newer, more effective therapies for nail fungus are important because onychomycosis remains a large unmet medical need, according to the NanoBio scientists. Oral systemic medications are plagued by serious hepatic and cardiac ...

Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift

... genital lesions, she added. NanoBio is currently testing its pipeline of topical products against a wide range of skin infections including onychomycosis (nail fungus), tinea capititis (ringworm) and acne. ...

Onychomycosis in Medical Technology

MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis

... a topical antifungal lacquer for the treatment of onychomycosis (nail fungus). The composite primary efficacy ... expert panel assessed clinical photographs of 37 onychomycosis patients who completed 48 weeks of ... designed, with the assistance of well-known onychomycosis experts, to address three important objectives: ...

NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis

... its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain ... the nail bed where dermatophytes responsible for onychomycosis reside. It then kills both active hyphae and ... Candida albicans. About Onychomycosis onychomycosis is a chronic, persistent fungal infection of the ...

NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008

... treatments for herpes labialis (cold sores) and onychomycosis (toe nail fungus) at the annual meeting of the ... provide a significant advance for onychomycosis therapy in terms of safety." Current oral (systemic) drugs for onychomycosis pose risks of hepatic and cardiac toxicity, as ...

New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects

... currently approved systemic medications for onychomycosis carry serious risks of cardiac and ... "At present, the vast majority of people with onychomycosis are untreated as a result of concerns for the ... NB-002 is potentially the first treatment for onychomycosis that is highly efficacious and very safe." ...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

... of topical products against a wide range of skin infections including onychomycosis (nail fungus), tinea capititis (ringworm) and acne. About NanoBio ... lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne and a broad platform of mucosal vaccines. The ...

Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections

... CEO Bill Cumbie, "is to develop a safe and effective treatment for onychomycosis that can be accessed by a large number of people at a low cost. Many ... the way to being the first phototherapy treatment approved by the FDA for onychomycosis with its research published in the prestigious peer-reviewed British ...

NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones

... topical lotions NB-001 for herpes labialis (cold sores) and NB-002 for onychomycosis (nail fungus). Additionally, the funding has supported extensive animal ... lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. ...

Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis

... derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne and cystic fibrosis and a broad range of intranasal vaccines. The company's headquarters and laboratory facilities are located in ...

NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy

... from its patented NanoStat(TM) technology platform. The company's lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located ...

NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis

... derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann ...

Onychomycosis in Medical Dictionary

Onychomycosis

... onychomycosis , proximal white subungual : The rarest form ... fungus infection of the finger or toenail. onychomycosis is difficult to treat because nails grow slowly ... including oral and topical medications. onychomycosis - A fungal infection that involves the ...

Proximal

... to the body. Proximal white subungual onychomycosis is diagnose d based upon its unusual location ... all the way across the palm. Candida onychomycosis is a yeast infection of the nail that causes ... fungal nail infections . Proximal subungual onychomycosis accounts for less than 1% of all fungal nail ...

Fungus

... in the treatment of nail fungus ( tinea unguium, dermatophytic onychomycosis , onychomycosis , ringworm of the nail). The pulse dosing regimen is 200 mg b.i.d. ...

Nail fungus

... in the treatment of nail fungus ( tinea unguium, dermatophytic onychomycosis , onychomycosis , ringworm of the nail). The pulse dosing regimen is 200 mg b.i.d. ...

Ringworm

... in the treatment of nail fungus ( tinea unguium, dermatophytic onychomycosis , onychomycosis , ringworm of the nail). The pulse dosing regimen is 200 mg b.i.d. ...

Subungual

... from a direct injury to the fingernail. Proximal white subungual onychomycosis is diagnose d based upon its unusual location (in the portion of the ... the extensive damage but it usually grows back. Distal subungual onychomycosis (DSO) is the most common type of fungal nail infection . It is caused by ...

Tinea

... in the treatment of nail fungus ( tinea unguium, dermatophytic onychomycosis , onychomycosis , ringworm of the nail). The pulse dosing regimen is 200 mg b.i.d. ...

Ungual

... a direct injury to the fingernail. Proximal white sub ungual onychomycosis is diagnose d based upon its unusual location (in the portion of the ... the extensive damage but it usually grows back. Distal sub ungual onychomycosis (DSO) is the most common type of fungal nail infection . It is caused by ...

Candida

... diabetes , who no longer use tobacco (the cause of almost all emphysema in persons younger than 75), and who have $50, ... Another type of onychomycosis is caused by yeast ( candida albicans or candida parapsilosis). These infections are less common and produce similar symptoms. These ...

Circulation

... flow of blood through the veins and also stimulates the nerve s which control the blood vessels. Patients with diabetes commonly develop onychomycosis because blood circulation is poor in the extremities, and the body's ability to fight infections is compromised. Stasis dermatitis - ...

More>>

Onychomycosis in Biological Technology

NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists

... lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, and a broad platform of mucosal vaccines. NanoBio has ... recurrent herpes labialis. A large phase 2 trial is nearing completion in onychomycosis and clinical trials are planned for acne and an influenza mucosal vaccine ...

Daniel B. Dubin, M.D., Joins NanoBio Corp.'s Board of Directors

... the strategic positioning of our topical treatments for herpes labialis, onychomycosis and other dermatologic infections." A Harvard-trained dermatologist, Dr. ... lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. ...

David M. Stout Joins NanoBio Corporation's Board of Directors

... fungi. They include topical treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and bacterial skin infections (including MRSA), as well as ... lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for influenza and hepatitis B. The ...

Arpida Announces Full Year 2007 Financial Results

... the acquisition of TLT Medical Ltd. The transaction regarding TLT's onychomycosis treatment comprises an upfront payment as well as success-dependent future ... of TLT Medical Ltd. The acquisition was finalised in August 2007. onychomycosis (OM) is a fungal infection affecting mainly toenails and, to a lesser ...

Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis

... for enrolment into the pivotal Phase III study with the TLT treatment in onychomycosis has been initiated and is progressing at a very good rate. Approximately ... on track to complete this trial by early 2009." About onychomycosis onychomycosis (OM) is a fungal infection affecting mainly toenails and, to a lesser ...

NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions

... The exclusive agreement is worldwide in scope, with the exception of certain Asian markets, and covers all major dermatological conditions, excluding onychomycosis (nail fungus) and orphan drug indications. Under the terms of the agreement, NovaBay expects to receive from Galderma up to $50 million upon ...

NanoBio Corporation Raises $12 Million in Series B Financing

... derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in ...

NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008

... from its patented NanoStat(TM) technology platform. The company's lead clinical product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and mucosal vaccines for influenza and hepatitis B. Company headquarters and laboratory facilities are located ...

Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.

... for the treatment of diabetic foot infection that has already completed two Phase 3 clinical trials; EcoNail, a novel topical treatment for onychomycosis that is currently in a Phase 2 clinical trial. Macrochem also has two proprietary dermatology drug platforms, SEPA(R) and MacroDerm. The acquisition ...

FierceBiotech Names NanoBio Corporation as One of the 'Fierce 15' Biotech Companies of 2008

... derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann ...